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Abstract
It is estimated that 54,000 new cases of Head and Neck Cancer will be diagnosed in the
United States in 2021 (Cancer Facts and Figures, 2021). Head and Neck cancers
represent those that originate from sites which include the nasopharynx, oropharynx, oral
cavity and hypo-pharynx. In advanced cases, treatment modalities are combined to
include surgery, radiation and chemotherapy. Expected side effects of treatment can
include mucositis, dysgeusia, dysphagia, odynophagia, nausea, vomiting and xerostomia.
These toxicities can contribute to dehydration, weight loss and malnutrition. This paper
examines the current state of evidence as it pertains to nutritional outcomes for Head and
Neck cancer patients receiving concurrent chemotherapy and radiation when prophylactic
percutaneous endoscopic gastrostomy (PEG) tubes versus reactive tubes were used. A
retrospective chart review was conducted to examine the following research question:
Does prophylactic percutaneous gastrostomy tube placement improve nutritional
outcomes in patients receiving concurrent chemotherapy and radiation for Head and Neck
Cancer patients when compared to those patients with reactive PEG tubes placed. The
results of this study identified that despite timing of tube placement, patients in both
groups lost weight and showed signs of worsening nutritional outcomes as evidenced by
decreased body mass index, total protein, and albumin levels. Advanced practice nurses
are in a unique position to develop innovative approaches to enhance nutrition in this
patient population. Risk assessment tools, interdisciplinary collaboration and the
development of a Head and Neck cancer pre-habilitation clinic may improve nutritional
outcomes in the Head and Neck cancer patient receiving cancer treatment.
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Prophylactic Percutaneous Endoscopic Gastric Tubes for Head and Neck Cancer: Are
They Worth Their Weight?

Background/Statement of the Problem
Head and Neck cancer refers to malignancies that include the lip, oral cavity,
pharynx, larynx and para nasal sinuses. In the United States, it is estimated that over
54,000 new cases of Head and Neck cancer will be diagnosed in 2021 (Cancer Facts and
Figures, 2021) and greater than ninety percent of these patients are determined to have
squamous cell pathology. Tobacco and alcohol have been identified as the most common
causative agents which contribute to the development of this complex disease. Patients
with Head and Neck cancer are also at an increased risk for secondary primary cancers of
the Head and Neck as well as cancers of the aero digestive tract.
Treatment modalities for these cancers include surgery, chemotherapy,
immunotherapy and radiation alone or in combination. Treatment is complicated and
guided by site of disease, stage and pathological findings. A multitude of physical and
functional impairments result from treatment related toxicities, disease itself and health
behaviors. Nutritional complications are often present before treatment is initiated if the
tumor is present in the oral cavity or throat (Lees, 1999). Pain, xerostomia, mucositis,
and impaired swallow function negatively affects the patient’s ability to maintain
adequate nutrition and hydration. Malnutrition has been associated with hospitalizations,
treatment interruptions, decreased treatment efficacy and diminished quality of life.
Percutaneous endoscopic gastrostomy (PEG) tubes for enteral feeding in patients
with Head and Neck cancer, undergoing multimodal therapy, is often utilized to provide
nutritional support in this at-risk population (Kasozi et al., 2018). Percutaneous
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endoscopic gastric (PEG) tubes may be placed prophylactically in anticipation of patient
needs prior to beginning treatment or reactively, during or after treatment, when the
patient can no longer meet their nutritional requirements. Prophylactic PEG tube
placement is a common practice despite the lack of research to support the procedure.
Although PEG tube placement timing is discussed frequently in the literature, there is no
consensus on whether prophylactic versus reactive placement for Head and Neck cancer
patients is preferable (Locher et al., 2011).
The National Comprehensive Cancer Network (NCCN) does not recommend the
placement of prophylactic PEG tubes in patients with very good performance status or for
patients without significant pre-treatment weight loss, significant airway obstruction or
severe dysphagia. However, the NCCN guidelines state that PEG tubes should be
strongly considered if patients have severe weight loss prior to treatment. Percutaneous
endoscopic gastric tubes should also be considered if patients experience ongoing
dehydration, dysphagia, anorexia or pain which prohibits the ability to eat or drink.
Aspiration risk, comorbidities, radiation field and impaired swallow function are other
factors that influence prophylactic tube placement in the Head and Neck cancer patient.
The purpose of the Cochrane Systematic Review was to compare the
effectiveness of different enteral feeding methods (PEG vs. nasogastric) used in the
nutritional management of patients with Head and Neck cancer receiving radiotherapy or
chemo radiotherapy using clinical outcomes, nutritional status, quality of life and rates of
complications (Nugent et al., 2011). There was insufficient evidence to make a
determination on the optimal method of enteral feeding. Timing of tube placements were
not studied. Although PEG tube placement is considered relatively safe, complications
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can occur. Infection, tube obstruction, migration and dislodgement are common
occurrences. More serious complications such as peritonitis, abscess or fistula
development are rare (Riera, 2002). Long term negative outcomes with PEG tube
placements include tube dependency, loss of swallow function, and metastasis or seeding
at the PEG tube site. Furthermore, some prophylactic PEG tubes placed may never be
used. It is important to assess each patient and weigh the risks and benefits of
prophylactic versus reactive tube placement while considering the potential effects on
quality of life. Because the decision to place a PEG tube often relies on patient values
and clinician preferences, additional research is needed to understand the use of
prophylactic feeding tube placement in this compromised patient population and provide
evidence based guidelines that can be followed by care teams. The purpose of this study
is to describe nutritional outcomes in the Head and Neck cancer population receiving
concurrent chemotherapy/radiation in those patients with prophylactic endoscopic gastric
tubes versus those with reactive ones.
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Literature Review
A literature review was conducted using the Cumulative Index of Nursing and
Allied Health Literature (CINAHL) and PUB MED databases. Keywords used included
combinations of head and neck cancer, neoplasm, prophylactic PEG tube, PEG, nutrition
and malnutrition. Literature was searched between 2011 and 2019. Study indexes
included English language and full-text. Thirteen research articles retrieved and six were
selected for literature review.
Percutaneous Endoscopic Gastric Tube Placement
Most patients with Head and Neck cancer lose weight and are nutritionally
compromised as a result of their disease, health behaviors and treatment-related toxicities
making nutritional management important (NCCN, 2020). Feedings through
percutaneous endoscopic gastric (PEG) tubes, whether placed prophylactically or
reactively, has become a relatively common practice in this population (Langius et al.,
2013). Although PEG tube placement is considered relatively safe and has a low rate of
significant associated complications, it brings both risks and benefits. Currently, criteria
for patient selection regarding PEG tube placements are not standardized and there are no
published criteria or national guidelines on the optimum method of enteral tube feeding
in this patient group (Nugent et al., 2010). More research is needed to inform and guide
provider decisions in regards to PEG tube placement and timing.
A 2011 comprehensive review conducted by Locher et al., (2011) sought to
describe the prevalence of PEG tube placement in patients undergoing treatment for Head
and Neck cancer, describe factors associated with PEG tube placement at any time and to
describe the reported and potential benefits and risks associated with PEG tube
placement. Seven hundred thirty-nine articles were identified for review and the authors
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identified multiple benefits for prophylactic feeding tube placement. Benefits included
decreased weight loss, hospitalizations and treatment interruptions. For example, one
study included in this review was a prospective randomized trial by Salas et al., (2009).
Researchers assigned Head and Neck cancer patients without nutritional deficits (prior to
chemotherapy/radiation) to either receive prophylactic PEG tube or no PEG tube
placement. At six months, quality of life scores were higher in the prophylactic PEG
placement arm. Despite a small sample size, these findings suggest that further studies
on PEG placement timing and quality of life may be of clinical interest.
Locher et al., (2011) identified that although there is no consensus in the literature
to determine when PEG placement is preferable, it is an important and relevant clinical
issue. A gap in the literature exists as there is a lack of research looking into the use of
prophylactic PEG tube placement and outcome evaluations in the Head and Neck cancer
population. In conclusion, more research is needed to guide physician practice when
determining if prophylactic PEG tube placement in warranted in the treatment of Head
and Neck cancer patients.
A retrospective chart review by Sachdev et al., (2015) conducted a detailed
analysis of clinical and dosimetric parameters to better define factors that could predict
requirements for enteral feeding. Dosimetric parameters were defined as the mean dose,
maximum dose and minimum dose of radiation to head and neck structures. The
investigators goal was to determine high risk patients with an objective to maximize
targeted nutritional guidance, early supplementation, swallowing therapy and more
aggressive symptomatic support. The second aim was to determine if the research
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derived in this study could support delays or prevent placement of a feeding tube thus
preventing associated long term complications (Sachdev et al., 2015).
One hundred patients with locally advanced stage III and IV Head and Neck
Squamous Cell Carcinoma were chronologically selected for study at Northwestern
University Medical Center between 2005 and 2010. Patients were excluded if their
cancer stage was I or II, if a different treatment modality was administered and/or if a
feeding tube was placed prior to treatment. All patients were retrospectively analyzed
after intensity-modulated radiation therapy was completed. Ninety seven percent of
patients received a combination of radiation and chemotherapy. Patients were referred
for a percutaneous endoscopic gastric tube if their weight loss exceeded ten percent due
to reduced oral intake. Univariate and multivariate analyses using logistic regression
were used to determine clinical and dosimetric factors associated with needing enteral
feeding (Sachdev et al., 2015). Fischer’s exact tests and Wilcoxon rank-sum tests were
also used for analysis.
Thirty-three percent of patients required placement of an enteral feeding tube.
The median time to tube placement was twenty five days from start of treatment. On
univariate and multivariate analysis, age remained the only statistically significant factor
(p=0.003) regardless of other clinical features and all radiation planning parameters
(Sachdev et al., 2015). In conclusion, age was found to be the most significant risk factor
for needing a feeding tube in this patient population. This research supported
maximizing early nutritional guidance, targeted supplementation, and symptomatic
support in patients older than sixty receiving concurrent chemotherapy and radiation.
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Interventions may result in a delay or omission of enteral feeding theoretically reducing
long term feeding tube complications such as tube dependence (Sachdev et al., 2015).
Risks and Benefits of Percutaneous Endoscopic Gastric Tube Placement
Percutaneous endoscopic tubes can provide both risks and benefits in the Head
and Neck cancer patients receiving concurrent chemotherapy/radiation. Percutaneous
endoscopic gastric tubes have been found to be effective in maintaining body weight and
preventing malnutrition in this patient population. Percutaneous endoscopic gastric tubes
may decrease morbidity related to poor nutritional intake during cancer treatment and
possibly prevent dehydration and unplanned hospitalizations (Bishop & Reed, 2015).
Having a PEG in place may also improve treatment compliance and quality of life
(Madhoun et. al., 2016). Alternatively, infection, tube malfunction/migration are all
common risks associated with tube placement. Still, other data suggests even greater
risks. For example, enteral feeding can induce long term tube dependence and disuse of
the swallowing mechanism which has been linked to complications such as prolonged
dysphagia and esophageal constriction (Sachdev et. al., 2015). Although infections and
tube malfunction are more commonly seen adverse events associated with PEG tube
placement, rare cases of seeding at the PEG site have also been reported (Cady, 2007).
Harm has been associated with prophylactic PEG tube placement. Various
complications such as infection, tube complications, alterations in elimination, sodium
and glucose alterations, gastric bleeding, peritonitis, cellulitis, ileus, perforation, pain,
gastric metastases and anesthesia risks were reported (Locher et al., 2011). Furthermore,
researchers have found that PEG dependence is a leading clinical predictor of quality of
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life in this patient population. Body image disturbance and loss of swallow function were
also predicted to be a consequences of prophylactic PEG tube placement.
A systematic review completed by Orphanidou et al., (2011) studied prophylactic
feeding tubes for patients with locally advanced Head and Neck cancer undergoing
combined chemotherapy and radiotherapy. The goals of this systematic review were to
determine risks and benefits of prophylactic feeding tubes in the curative Head and Neck
cancer population receiving combination chemotherapy/radiation and to make
recommendations on the use of prophylactic feeding tubes and nutrition.
Studies were eligible for inclusion in the systematic review if they were published
as full reports or publicly available abstracts in 1985 or later. Participants in these
eligible studies were adult patients with squamous cell carcinoma of the head and neck
receiving combined chemotherapy/radiation with curative intent, either as primary
therapy or after surgery, who had a PEG tube placed prior to treatment. Twenty-one
eligible studies were found. None were randomized or quasi-randomized trials.
Available studies were descriptive, four were prospective and 11 studies included a
control group.
Orphanidau et al., (2011) reported available evidence as weak. Therefore, the
researchers could not conclude the effectiveness of prophylactic feeding tubes in the
Head and Neck cancer population receiving concurrent chemotherapy and radiation in
curative intended patients. Insufficient quality and quantity of the evidence, difficulty
with data analysis and patients lost to follow up were identified as study limitations.
Furthermore, the body of evidence reviewed could not support an evidence-based clinical
practice guideline, however, recommendations were made.
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Recommendations include using a comprehensive interdisciplinary approach in
the care of the Head and Neck cancer patient before, during and after treatment
commences (Orphanidau et al., 2011). Investigators also point out that having a
nutritional screening and referral process in place to identify patient at risk or
experiencing malnutrition is essential. Validated nutritional screenings tools are also
necessary. Assessment and interventions are meant to optimize nutrition and fluid intake,
consider patients for tube placement, provide symptom management and preserve
swallow function. Rehab referral to speech and language pathology can focus on
resumption of oral intake in an effort to prevent tube feed dependence.
The purpose of Alshadwi et al., (2013), literature review was to assess the current
literature supporting the benefit of nutritional support, patient assessment and nutritional
repletion, and the advantages and disadvantages of various alimentation modalities.
Articles were reviewed that focused on the etiology and assessment of malnutrition and
current nutritional treatments for cancer-induced anorexia and cachexia. Two hundred
forty-eight articles were found and a summative view was formulated.
Investigators concluded that nutritional interventions should be initiated before
cancer treatment begins (Alshadwi et al., 2013). Researchers summarized that
gastrostomy tube placement before radiation therapy has been shown to prevent weight
loss, treatment interruption, and dehydration (Alshadwi et al., 2013) and percutaneous
endoscopic gastric tubes are preferred for patients who require tube feeds for more than
thirty days.
One prospective multi-institution study of one hundred seventy two patients was
reviewed. It compared PEG tubes with gastric tubes. According to this literature review,
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gastric tubes had increased mortality rates and major complications. However, PEG tube
placements were noted to have cancer cell seeding at the insertion site and tumor
implantation after endoscopic placement (Alshadwi et al., 2013). Although reported as
an incidence of up to one percent, it is worth noting. In conclusion, researchers
summarized that for high risk Head and Neck cancer patients who are unable to consume
nutrition by mouth, enteral feeding must be provided.
Dysphagia
Difficulty swallowing can be a presenting symptom in the Head and Neck cancer
patient or a side effect of cancer treatment. The tumor location itself can often cause
nutritional complications before treatment begins, with 5–52% of patients reporting
dysphagia before undergoing CRT or RT (Platteaux et al., 2010). Dysphagia and
swallow function can be measured by clinical swallow assessments or by video
fluoroscopic swallow studies. More common indicators or swallowing problems are
weight loss, food intake or need for PEG tube intervention (Langmore et al., 2012).
A randomized controlled clinical trial by Silander et al., (2013) followed Head
and Neck cancer patients for two years to measure their energy intake, choice of energy
sources and to assess problems with dysphagia. Energy intake in defined as oral,
nutritional supplements, enteral and parenteral sources of nutrition. The objective was to
explore when and for how long the patients had dysphagia and lost weight due to
insufficient intake, and if having a PEG tube in place made a difference.
The population was identified as patients with stages III or IV oral or pharyngeal
cancer and included curative patients. One hundred thirty-four patients were included
and randomized to either a prophylactic PEG for early enteral feeding or nutritional care
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according to clinical practice. At seven time points, weight, dysphagia, and energy intake
was measured (Silander et al., 2013). Quality of life was measured using the European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire
(EORTC-35) (Silander et al., 2013). Food calculation software program AIVO Diet 32
analyzed intake data. Group comparisons were done using the Mann-Whitney U-test,
Fisher’s Exact test and Mantel-Haenszel x2 for comparisons. Statistical analysis was
performed using SAS software. Findings were reported using statistically significant data
analysis.
Both groups lost weight in the first six months due to insufficient energy intake
and used enteral nutrition as their main intake source. No significant differences between
groups were found. Neither of the groups reached their recommended protein
requirements until six months after the start of treatment. Although dysphagia was
prevalent, after one year, dysphagia had decreased, and oral intake was the main energy
source for both groups. Study results concluded that a prophylactic PEG did not
significantly improve enteral intake (Silander et al., 2013).
Nutrition
Nutritional management is very important in head and neck cancer patients to
improve outcomes and to minimize significant temporary or permanent treatment-related
complications such as severe weight loss (NCCN, 2020). All patients should be
evaluated for nutritional risks and receive nutrition counseling by a registered dietician
and have appropriate interventions made. Percutaneous endoscopic gastric tubes may be
recommended prior to or during treatment for patients at high risk for significant weight
loss and malnutrition.
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Langmore et al., (2012) looked at whether PEG tube use caused dysphagia in
Head and Neck Cancer patients undergoing radiotherapy. The first aim was to determine
whether patients who received a prophylactic PEG had better or worse swallowing
function, diet scores, or weight change outcomes than patients who did not receive a
prophylactic PEG tube. The second aim of the study was to compare whether patients
who used a feeding tube for all, some, or none of their nutrition, fared differently in terms
of their swallow ability, diet level and weight change. A retrospective chart review was
conducted for all Head and Neck cancer patients treated with radiation at the Boston
University Medical Center from January 2003 to September 2008. Fifty nine patients
met all inclusion and exclusion criteria.
Analyses were conducted to determine the impact of PEG use on long-term diet
level and weight change (Langmore et al., 2012). The investigators first evaluated
whether patients who received prophylactic PEG had different outcomes (percentage of
weight change and diet scores) than patients who did not receive a prophylactic PEG
tube. Second, researchers assessed whether diet level at the end of radiation for all
patients were associated with percentage of weight change and diet scores (Langmore et
al., 2012). Data was collected at four capture points: the end of radiation and then again
at 3, 6, and 12 months post placement. For each analysis, linear mixed-effects models
were used to evaluate relationships. Kruskal-Wallis tests were used to analyze the
association between diet status at baseline and diet scores at each time point. For the diet
level analysis, Tukey-Kramer method was used to identify significant pairwise
differences across the different baseline diet groups. Analysis was performed using SAS
software.
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Results showed no statistically significant differences of weight loss between the
two groups at each time period (Langmore et al., 2012). In contrast to weight change
results, the prophylactic PEG group had significantly worse diet outcomes than those
who did not have prophylactic PEG tubes. However, those who did not receive
prophylactic PEG’s and those who maintained an oral, or a partial oral diet during
radiation, had significantly better diet outcomes at all touch points post radiation
(Langmore et al., 2012).
A 2017 study of early prophylactic feeding versus standard care in patients with
Head and Neck cancer was completed by Brown et al. The purpose of the study was to
evaluate the effectiveness of early prophylactic tube feeding compared to beginning tube
feeding during treatment in patients undergoing prophylactic tube placement for patients
with Head and Neck cancers. One hundred and seventy four patients were invited to
participate in the study between September 2012 to June 2015 with 131 patients recruited
then randomized. The primary outcome measure was the percentage of weight loss at
three months post treatment (Brown et al., 2017). This was a single-center randomized
controlled trial conducted in Queensland, Australia.
In the standard care arm, patients were started on enteral nutrition via their
prophylactic gastrostomy by the dietitian when oral intake was less than 60 percent of
estimated nutritional requirements for greater than ten days, if the patient was losing
weight, if the patient required diet modification of texture, or if the patient experienced
and increase in symptoms which impacted their nutritional status. The intervention group
had enteral nutrition initiated via their prophylactic gastrostomy immediately following
tube placement prior to the start of treatment. The prophylactic enteral nutrition was in
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addition to their current oral intake and consisted of two 200ml bolus feedings daily
(Brown et al., 2017). Data was analyzed and found no significant differences for weight
loss, body composition or nutritional status. Researchers concluded that early
intervention did not improve patient outcomes.
P16 Tumor Suppressor Gene
An important gene product that is involved in Head and Neck squamous cell
carcinoma (HNSCC) pathogenesis is the p16INK4a (p16) protein, made by
the p16INK4a (CDKN2A) gene. P16 is a cyclin-dependent kinase inhibitor that inhibits
pRb phosphorylation and blocks cell cycle progression at the G1 to S check point (Lo et
al., 1999). Loss of p16 expression by deletion, mutation, or hypermethylation is common
in HNSCC (Worsham et al., 2006) and is associated with a worse prognosis (Namazie et
al., 2009). P16 expression (p16 positive) has been correlated with improved outcomes in
oral pharyngeal squamous cell carcinoma (Weinberger et al., 2004). The biologic
significance of HPV positivity includes improved prognosis for patients with HPV
positive HNSCC relative to HPV negative HNSCC (Ang et al., 2010) due in part to a
better therapeutic response to chemo/radiotherapy (Fakhry, et al., 2008).
Verma et al., (2015) explored variables associated with poor prognosis in postoperative p16 positive oropharyngeal squamous cell carcinoma patients receiving
adjuvant radiotherapy or chemo-radiotherapy in relation to feeding tube insertion timing.
Ninety-seven patients were eligible for this retrospective chart review which took place
between 1997 and 2009. Patients were grouped by those who had feeding tubes placed
before radiation, patients who had feeding tubes placed during or after radiation, and
patients who had no feeding tubes placed. These groups were analyzed for differential
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tumor, patient, treatment, feeding tube characteristics as well as overall survival, disease
free survival, and distant metastasis free survival (Verma et al., 2015).
The study population was identified as oropharyngeal cancer patients who were
p16 positive, post-operative and adjuvant radiation candidates (Verma et al., 2015). After
inclusion and exclusion criteria was met, ninety-seven patients were left for analysis.
The primary endpoints were overall survival, disease free survival and distant metastases
free survival. Kruskal-Wallis, Fisher Exact tests, Kaplan-Meier curves, Cox
proportional Hazard Models and a backward stepwise model selection approach were
performed for statistical analysis.
Results showed that pre-radiation feeding tube insertions were associated with
higher tumor size and depth, tumor (T) but not node (N), overall stage, comorbidities,
presence of chemotherapy, and less use of trans-oral laser microsurgery (Verma et al.,
2015). Time from surgery to intensity modulated radiation therapy completion was
statistically longer in patients receiving prophylactic PEG tubes. The feeding tubes were
permanent in fifty-two percent of patient receiving prophylactic PEG tubes versus sixteen
percent in the patient group who received PEG placement during or after treatment
completion. Five year overall survival rates were highest in patients without feeding
tubes (90%) and lowest in patients with feeding tubes placed prophylactically (50%).
Five year disease free survival (DFS) was highest in the patients without feeding tubes
(87.6%) and lowest for patients who had prophylactic PEG tubes placed (42.7%).
Multivariate analysis showed that for both overall survival and disease free survival,
feeding tube placement time and smoking history were statistically significant (Verma et
al., 2015). This study concluded that early feeding tube insertion was correlated with a
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poor prognosis. The presence of a feeding tube at the time of radiation consult can be
used as an alternate marker in the p16 positive oropharyngeal squamous cell carcinoma
patients to identify worse disease status alerting clinicians that this patient population is
in a higher risk sub group.
PEG Tube Placement Timing
For Head and Neck cancer patients undergoing treatment, there are two
approaches to PEG tube feeding. Percutaneous endoscopic gastric tubes may be placed
prophylactically in anticipation of patient needs prior to treatment, or reactively during
treatment at a time when the patient is no longer able to meet their nutritional
requirements (Bishop & Reed, 2015). Each method is associated with advantages and
disadvantages. Advantages of prophylactic PEG insertion include decreases in weight
loss, malnutrition and dehydration related hospitalizations and less treatment
interruptions. Disadvantages to prophylactic tube placement include risks posed from
surgery and non-use. Reactive tube placement, however, often interrupts treatment.
There is no consensus on whether prophylactic versus reactive placement of PEG tubes is
preferable in Head and Neck cancer patients (Locher et al., 2011).
A study by Kramer et al., (2014) looked to examine the outcomes of PEG tube
placement timing (prophylactic vs. reactive) on weight loss, tube duration and disease
control in patients with Head and Neck cancer. The design was a historical cohort study
with seventy-four patients identified for inclusion. The population included those Head
and Neck patient’s having received platinum-based chemotherapy and radiation as a
primary modality and those patients with primary surgical resection having received
adjuvant chemotherapy and radiation. Percutaneous endoscopic gastric tube timing was
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determined by patient and/or physician preference to be either prophylactic (before
radiation began) or reactive (after radiation began) (Kramer et al., 2014).
Data was gathered, tabulated and analyzed to determine the effect of PEG tube
placement timing on nutritional status-in which weight gain and survival were
determined. A second goal was to assess the effect of placement timing on PEG tube
dependence and length of usage (Kramer et al., 2014). Student independent t-tests
compared continuous variables and chi square and Fisher’s exact tests analyzed
categorical variables (Kramer et al., 2014). A hierarchical multiple regression analysis
controlled confounders. Kaplan-Meier analysis looked to determine if timing had an
effect on PEG use. Software then analyzed this data.
Researchers found that patients with prophylactic tube placement and advanced
tumor stage had longer PEG tube duration. Patients receiving reactive PEG tubes had
them in place for fewer days than those placed prophylactically (227 versus 139 days,
p<.01). No difference in percentage weight loss was found at 2, 6 or 12 months. Kramer
et al., (2014) concluded that patients who receive reactive PEG tube placement may have
them in for shorter durations of time without an increase in weight loss or worse
outcomes. Furthermore, the study showed that having a prophylactic PEG tube did not
significantly improve enteral intake.
A retrospective study by Lang et al., (2020) evaluated the period of time between
radiation initiation and PEG tube placement. A secondary aim was to evaluate the course
of weight change following PEG placement (Lang et al., 2020). A retrospective chart
review was conducted for Head and Neck cancer patients undergoing radiotherapy alone,
or chemotherapy/radiation between January 2010 and August 2017 at the University
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Hospital of Heidelberg. All patients with Head and Neck cancer who underwent PEG
tube placement before or during radiation were included in this study. Patients receiving
either concurrent chemotherapy or immunotherapy with radiation were also included.
One hundred and eighty six patients were included in this study.
A retrospective analysis was conducted to determine initial weight and nutritional
intake prior to radiation initiation and then followed throughout treatment until
completion. Demographic characteristics, body weight, body mass index (BMI), oral
intake and patient-reported dysphagia and treatment related toxicities were examined
(Lang et al., 2020). Statistical analysis was conducted and results presented as means and
percentages. Kaplan-Meier estimates were calculated and Univariate analysis was
conducted using logistic regression analysis. For comparison between groups, chisquared and Student t-tests were performed. IBM SPSS software analyzed the data.
This study demonstrated that patients with an initial low BMI (<18.5 kg/m2) and
patients with pre-existing tumor-associated dysphagia were significantly more likely to
receive earlier PEG placement. Therefore, the examiners concluded that this subset of
patients should be closely monitored for weight loss and decreased oral intake to
determine the need for early PEG tube placement in an attempt to maintain adequate
nutrition, improve treatment tolerance and reduce side effects (Lang et al., 2020).
Twenty six patients had PEG tube insertion prior to radiation due to dysphagia and
reluctant weight loss. The remaining one hundred and sixty patients had PEG tube’s
placed during radiation therapy.
In conclusion, this literature review found no consensus to support prophylactic
PEG tube placement for improved nutritional outcomes within the Head and Neck cancer
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population prior to radiation/chemotherapy. Findings identify both benefits and harm.
Additional research is needed to further this study topic and nutritional outcomes need
specifying. Additional study topics may include patient compliance, effects of alcohol
intake and insurance coverage for enteral products as they apply to the outcomes for
Head and Neck Cancer patients receiving concurrent chemotherapy and radiation.
Surgery, radiation and chemotherapy are effective modalities used in combination
or alone, to treat malignancies of the head and neck. However, surgery for head and neck
cancer can lead to facial disfigurement and functional disorders which can have a deep
impact on social interactions and emotional wellbeing. Body image disturbance, anxiety
and dysfunctional coping are psychological consequences which can occur from
disfiguring cancer treatment and PEG tube placement. Using Lazarus and Folkman’s
Theory of Stress, Adaptation and Coping, the emotional reactions to stress and relevant
coping factors of the Head and Neck cancer patient will be explored.
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Theoretical Framework
Lazarus and Folkman’s Theory of Stress, Adaptation and Coping evolved from
Richard Lazarus’ 1966 Appraisal Theory of Stress which is borrowed from the social
sciences. It is considered a stress theory which both explains and describes the
psychological response to stress. It is intended to be a practice level theory with metatheoretical roots (Lazarus & Folkman, 1984 p. xi). The concept of stress has historical
underpinnings beginning in the 14th century to present time with theoretical works
developed from various disciplines including biology, psychology, and social science
backgrounds (Lazarus & Folkman, 1984, p.3).
The basis of Lazarus’s original stress theory describes how a person copes
psychologically with stressful situations. Stress is considered to be a multitude of
variables and processes. The Theory of Stress, Adaptation and Coping, later developed
by Lazarus and Folkman, used this approach as the basis for their theoretical framework.
This framework aimed to examine the concept, specify antecedents, processes and
outcomes relevant to the overarching concept of stress (Lazarus & Folkman 1984, p. 12).
The theory’s intent was for practical use by a multitude of disciplines including nursing.
According to Lazarus and Folkman, there are two major factors which precede
stress. These factors are called antecedents. The first antecedent is the personenvironment relationship which includes values, beliefs, and social support among other
factors. The second antecedent is appraisal which is divided into three cognitive
subtypes. Primary appraisals refer to the judgments made about an event or stressor and
secondary appraisals evaluate how the individual responds to them. After additional
information has been received, the third subtype, re-appraisal occurs.
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Coping, per Lazarus, is the process in which threat is perceived and the appraisal
is managed (McEwen & Wills 2011, p. 289). The coping process is two-fold. Problemfocused coping changes the individual’s relationship with their environment whereas
emotional coping changes the situations meaning. The theory can be critiqued for not
applying categories that are mutually exclusive and fully exhaustive (Andersen & Jarden,
2012 p. 26). Re-appraisal and adaptation are results of successful coping. According to
Lazarus and Folkman, adaptation affects health, psychological well-being and social
functioning interdependently.
Coping theory is becoming increasingly relevant with the rising prevalence of
chronic diseases including cancer. The theory is particularly useful to oncology nurses
working with head and neck cancer patients who may not experience symptom relief.
Educating patients about effective coping strategies could provide benefit and potentially
improve quality of life for this patient population. Lazarus and Folkman’s Theory of
Stress, Adaptation and Coping has been utilized extensively in research as it relates to
head and neck cancer patients and coping.
A study by Andersen and Jarden (2012) explored how head and neck cancer
patient’s coped with radiation and associated side effects. The qualitative study applied
Lazarus and Folkman’s theory of coping to the final stage of the study’s research
analysis. Nine patients were eligible for study but only five were participants. Semistructured interviews were completed on this convenience sample.
General meaning was extrapolated from the interviews and themes were
developed. The Theory of Stress, Adaptation and Coping was applied to the findings
through further analysis to bring the main themes to a conceptual level (Andersen &
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Jarden, 2012, p. 26). The research question, “Which coping strategies do the patients
apply?” was answered in five main themes: Flying away, Recruiting help, Finding my
place, Cognitive Control and Coping. All main themes identified coping strategies which
were action oriented and improved quality of life when controlled by the patient.
Hulbert-Williams et al., (2012), also explored Lazarus and Folkman’s Theory of
Stress, Adaptation and Coping in full. Their aim was to investigate the validity of the
prescribed cognition-emotion relationships as outlined by Lazarus, using improved
methodological and statistical approaches. Their sample included 160 cancer patients
diagnosed with curative intent in which a diagnosis of psychosocial adjustment to cancer
was made.
A repeat measures design was used. A self-reported questionnaire was completed
soon after diagnosis, and at three and six month follow ups. Data on appraisals, corerelational themes and emotions were collected. Twelve core relational themes were
identified and the three most common included self-blame, loss/helplessness and threat.
Data collected in the study supported the structure of Lazarus and Folkman’s
theory and identified its sound empirical base. It was suggested by Hulbert-Williams et
al. (2012) that larger scale research is needed using more complex statistical testing. The
above research studies are examples that Lazarus and Folkman’s theory continues to be
relevant to the nursing profession.
The above research examples support the testability and usefulness of Lazarus
and Folkman’s Theory of Stress, Adaptation and Coping. The theory has been applied
extensively in nursing research and has been shown useful in practice. Emotional
wellbeing and effective coping is desired in all patient populations. Proper assessment of
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stress and coping will provide holistic care and provide proper referral for psycho-social,
supportive or palliative interventions. The application of stress theory to nursing practice
is important. It provides a framework for nurses to assess the effects of stress and the
coping processes that patients use. Identifying coping resources and support structures
and educating patients about them may facilitate effective coping strategies. Research
nurses, administrators, educators and bed-side nurses alike can incorporate Lazarus and
Folkman’s theory into practice. Next, a discussion of methodology.
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Method
Purpose
The purpose of this proposed research was to describe nutritional outcomes of
weight, body mass index, total protein and albumin and their relative change in the Head
and Neck cancer population receiving concurrent chemotherapy/radiation in those
patients with prophylactic percutaneous gastrostomy (PEG) tubes versus those without.
Design
The proposed study is a descriptive retrospective chart review of all Head and
Neck cancer patients treated with concurrent chemotherapy/radiation between January 1,
2000 and December 31, 2019 who are eligible. Patient’s electronic medical record data
meeting the criteria will be collected and analyzed.
Sample and Site
A convenience sample of all adult patients diagnosed with Head and Neck cancer
was obtained. Inclusion criteria for this study consisted of male and female patients with
Head and Neck cancer who received chemotherapy and radiation at Sturdy Memorial
Hospital and Brigham and Women’s/Sturdy Memorial Radiation Oncology Center. All
patients with Head and Neck cancer originating from sites which include the
nasopharynx, oropharynx, oral cavity and hypopharynx, regardless of HPV status were
included. This study also included adult patients who were treated with curative intent
for stages I-IV cancer with squamous cell pathology and had PEG tubes placed either
before (prophylactically) or during (reactively) chemotherapy/radiation administration.
Exclusion criteria omitted patients with Stage 0 Head and Neck cancer, patients with
recurrent or metastatic disease and those who did not complete chemotherapy/radiation.

25

Patients with histological Head and Neck cancer pathology types other than squamous
cell and patients treated with palliative intent were be excluded.
Procedures
Institutional Review Board approval was obtained at Sturdy Memorial Hospital
and Rhode Island College prior to the study. Other ethical considerations included
research ethics and compliancy training (CITI program), HIPPA, data protection and
patient confidentiality.
Measurement
The data collection plan identified for this retrospective chart review included
recording quantitative data found within the hospital’s electronic medical record systems
which included Meditech, Centrictiy, Intellidose, Intellidose TXM and/or Cerner. Data
collection included the Eastern Cooperative Oncology Group performance status, ICD-10
code, tissue of origin, cancer stage, treatment protocol, PEG tube placement and timing
of tube placement. Weight, body mass index, total protein and albumin levels were
captured at baseline, prior to beginning cancer treatment and again upon completion of
treatment. The data was collected and analyzed by one evaluator. A Microsoft Excel
spread sheet was used for data organization, management, and storage.
Dissemination
The proposed research will be disseminated as a major paper on the Rhode Island
College Digital commons website. A poster presentation will be completed. The poster
will also be presented at the Sturdy Memorial Hospital quality fair. Professional
publication will be considered.
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Results
A total of 45 medical records were reviewed to obtain a cohort of 28 patients with
Head and Neck Cancer who received concurrent chemotherapy and radiation and who
had percutaneous endoscopic gastrostomy tubes placed. Group A included 27 subjects
(n=27) who had a percutaneous endoscopic gastrostomy tube placed prior to the initiation
of concurrent chemotherapy and radiation and Group B included 1 subject (n=1) who had
a percutaneous endoscopic gastrostomy tube placed after chemotherapy and radiation was
initiated. Data collected for both Group A and Group B included weight, body mass
index, total protein, and albumin levels. The mean, median and range were computed for
all categories of data collected and then compared between the two groups, then at two
catch points, prior to and upon completion of concurrent chemotherapy and radiation.
Table 1 summarizes the data collected in both Group A and Group B of patients prior to
the start of concurrent chemotherapy and radiation. Table 2 summarizes the data in both
groups of patients upon completion of concurrent chemotherapy and radiation.
Table 1 Comparison between Group A and Group B Pre-treatment
Weight
Group A
Prophylactic PEG tube
placement pre-treatment
Mean
Median
Range
Group B
Reactive PEG tube
placement pre-treatment
Mean
Median
Range

Body Mass Index

TP

Albumin

179.5
136.5
96-235

27.2
22.9
15.4-49.9

7.2
7.1
5.8-8.1

3.4
3.6
2.5-4.2

248

34.6

6.2

4
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Table 2 Comparison between Group A and Group B Post-treatment
Weight
Group A
Prophylactic PEG tube
placement posttreatment
Mean
Median
Range
Group B
Reactive PEG tube
placement posttreatment
Mean
Median
Range

Body Mass Index

TP

Albumin

169.6
131.5
93-340

25.7
22.1
14.8-47.4

6.8
6.7
5.7-8.6

3.3
3.3
2.4-4.3

230

32.1

6.1

3.7

Table 1 compares the weight, body mass index, total protein, and albumin scores
for two groups of patients, those who had PEG tubes placed prophylactically (Group A)
and those who had PEG tubes placed reactively (Group B) prior to concurrent
chemotherapy and radiation beginning. The weight range in Table 1 group A was
between 89 and 358 pounds with the mean weight being 179.5 pounds. The mean body
mass index for group A was 27.2 with the range being between 15.4 and 49.9. The mean
total protein level was 7.2 with the range being between 6 and 9.1. The mean albumin
level was 3.4 with the range being between 2.5 and 4. Group B contained only one
patient (N=1). Therefore, the measurements of weight, body mass index, total protein
and albumin reflect both the value and mean of this small data set of one patient. The
patient’s in Group A who had prophylactic PEG tubes placed prior to treatment weighed
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less, had lower body mass indexes and albumin levels but had higher total protein levels
when compared to the one patient in Group B.
Table 2 compares the weight, body mass index, total protein, and albumin scores
for two groups of patients, those who had PEG tubes placed prophylactically (Group A)
and those who had PEG tubes placed reactively (Group B) upon completion of
concurrent chemotherapy and radiation. The weight range in Table 2 Group A was
between 88 and 340 pounds with the mean weight being 169.6 pounds. The mean body
mass index for Group A was 25.7 with the range being 14.8 and 47.4. The mean total
protein level was 6.8 with the range being between 5.7 and 8.6. The range for albumin
was 2.4 and 4.1 with the mean being 3.3. Group B consisted of one patient (N=1),
therefore, the measurements of weight, body mass index, total protein, and albumin,
reflect both the individual value and the mean of this one patient data set.
Table 3 Comparison of average change percentages between Group A and Group B at
end of treatment
% Weight
change
Group A
Prophylactic
Peg Tubes
Group B
Reactive Peg
Tubes

%BMI
change

%Total Protein
change

%Albumin change

-5.48%

-5.35%

-4.4

-1.88

-7.26

-7.23

-1.61

-7.5

Table 3 compares the average percent change in weight, BMI, total protein, and
albumin levels for patients with prophylactic PEG tubes (Group A) versus patients who
had PEG tubes placed reactively (Group B) at the completion of treatment. Patients with
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prophylactic PEG tubes (Group A) had a 5.48% average decrease in weight upon
completion of treatment whereas the one patient with a reactive PEG tube (Group B), had
a 7.26% decrease in weight. Average decrease in body mass index for patients upon
treatment completion was 5.35% in Group A and 7.23% for the one patient in Group B.
The average percentage of decrease in total protein levels were greater in Group B (1.61%) than in Group A (-4.4 %). Albumin percentage decrease was also greater in
Group B (-7.5% versus -1.88%). This data suggests a greater percentage of weight loss,
decreased body mass index and albumin with less of a percentage decrease in total
protein for patients with reactive PEG tubes placed when measured upon completion of
concurrent chemotherapy/radiation treatment for Head and Neck Cancer.
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Summary and Conclusions
Approximately 35% to 60% of all patients with Head and Neck cancers are
malnourished at the time of their diagnosis because of tumor burden and obstruction of
intake or the anorexia and cachexia associated with their cancer (Alshadwi et al., 2013).
When administration of intensive multimodal treatments is concurrent, severe, and often
debilitating effects can compromise the patient’s ability to maintain adequate nutrition
and hydration (Orphanidou et al., 2011). Patients unable to maintain adequate oral intake
have greater rates of weight loss, hospitalization and forced treatment breaks (Bishop &
Reed, 2015). In Head and Neck cancer patients undergoing definitive chemotherapy and
radiation, there are two approaches to percutaneous endoscopic gastric tube feeding-first
to insert the tubes prior to treatment in anticipation of inadequate intake or second to
insert a tube when patients are no longer able to meet their nutritional requirements
(Bishop & Reed, 2015). There is no consensus on the optimal timing of PEG tube
placement for patients undergoing therapy for Head and Neck cancer (Kramer et al.,
2014).
The purpose of this study was to describe nutritional outcomes in the Head and
Neck cancer population receiving concurrent chemotherapy and radiation in those
patients with prophylactic endoscopic gastric tubes versus those with reactive tube
placements. This study was guided by Lazarus and Folkman’s Theory of Stress,
Adaptation and Coping. A retrospective chart review was conducted, and forty-five
charts were reviewed. Twenty- eight patients met the studies inclusion criteria and were
subsequently separated into two groups. Group A was Head and Neck cancer patients
with prophylactic endoscopic gastric tubes and Group B was Head and Neck cancer
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patients with reactive prophylactic endoscopic gastric tubes. A data collection tool was
developed based on literature and clinical experience which included patient weight,
body mass index, total protein, and albumin levels. Weight, body mass index, total
protein and albumin levels were captured at baseline, prior to beginning cancer treatment
and again upon completion of treatment then compared between the two groups. The
average change percentages of weight, body mass index, total protein and albumin were
also compared between Group A and Group B. The final sample size of Group A
included twenty-seven patients (n=27) and Group B had a final sample size of 1 patient
(n=1).
Table 1 compared weight, body mass index, total protein and albumin levels
between patients who had percutaneous endoscopic gastric tubes placed prophylactically
and reactively prior to beginning concurrent chemotherapy and radiation. The mean
weight, body mass index and albumin were lower in patients with prophylactic tubes
(Group A) when compared to those with reactive tubes placed (Group B) prior to starting
cancer treatment. Lower weight, body mass index and albumin levels in Group A
indicates that those patients having feeding tubes placed prophylactically may have had
significant pre-treatment weight loss, significant airway obstruction or severe dysphagia.
Table 2 compared the same data sets between patients who had percutaneous
endoscopic gastric tubes placed prophylactically versus reactively at the completion of
their cancer treatment. Again, average weight, body mass index and albumin levels were
found to be lower in patients with prophylactic tubes (Group A) when compared to those
with reactive tubes placed (Group B). This finding suggests that despite early
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intervention with gastric tube placement, patients continued to lose weight and show
signs of nutritional impairment upon completion of cancer treatment.
Table 3 compared weight loss, body mass index, total protein, and albumin
percent changes in patients with prophylactic percutaneous gastric tubes (Group A)
against those with reactive percutaneous gastric tubes (Group B) at the completion of
treatment. Although both groups had decreases in weight, body mass index, total protein
and albumin from their pre-treatment measures, patients with reactive tubes placed had a
greater percentage of decline in all touch points except total protein. This data identified
that prophylactic timing of tube placement did not prevent malnutrition and may not have
a significant impact on patients overall nutritional outcomes.
This study had many limitations. This research was limited by a small sample
size, in part, due to the low incidence of Head and Neck cancers which are relatively rare
and account for less than five percent of all cancer cases diagnosed in the United States
yearly. The study also took place in a community hospital setting, that lacks a designated
Head and Neck cancer clinic, which may have further attributed to the small sample size.
Other study limitations included the exclusion criteria. Nine patients had no
percutaneous gastric tubes placed, one patient never used their tube for artificial nutrition,
three patients did not complete their planned treatment protocols, and four medical
records had incomplete data sets. Therefore, these seventeen patients were excluded
from the study. The most significant limitation was the small sample size of patients with
reactive percutaneous endoscopic gastric tubes (N=1).
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It was noted in the patient’s medical records that of the twenty-seven patients who
had gastric tubes placed prophylactically, only nine patients started artificial nutrition
prior to their cancer treatment. These nine patients had an average of twenty-six days of
artificial nutrition prior to starting their cancer treatments. The remaining eighteen
patients started using artificial nutrition on an average of nineteen days after concurrent
chemotherapy and radiation started despite having had prophylactic percutaneous
endoscopic gastric tubes placed prior to their treatment’s initiation. Factors that may
have influenced artificial nutrition start time were personal preference, insurance
approval for artificial nutrition and gastric tube complications. Other factors for delaying
artificial nutrition could not be discerned. The one patient with a reactive percutaneous
endoscopic gastric tube had it placed eighteen days after treatment began and artificial
nutrition was started the same day. It is important to recognize that timing of tube
placement does not always coincide with timing of artificial nutrition commencing.
There is currently no consensus in the literature to guide the timing of tube placement.
Understanding the reasons that artificial nutrition is not started at time of tube placement
could glean pertinent information, identify barriers to care and help guide practice.
In summary, this research study described the nutritional outcomes in Head and
Neck cancer patients receiving concurrent chemotherapy and radiation who had
percutaneous endoscopic gastric tubes placed either prophylactically or reactively. The
study results identified that all patients, despite timing of tube placement, lost weight and
showed signs of worsening nutritional status. This was evidenced by decreases in body
mass index, total protein, and albumin in both patient groups. Identifying and eliminating
factors associated with delayed enteral nutrition may hasten tube to feed time and
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enhance patients overall nutritional status. More research is needed to assist clinicians in
choosing high risk patients who will likely benefit from gastric tube placement and low
risk patients who can forgo tube placement all together. Next, recommendations and
implications for advanced nursing practice will be discussed.
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Recommendations and Implications for Advanced Nursing Practice
The advanced practice registered nurse (APRN) plays a vital role in accurately
assessing the Head and Neck cancer patient prior to receiving concurrent chemotherapy
and radiation to determine if prophylactic feeding tube placement is indicated. A risk
assessment tool can be developed by the APRN using NCCN recommendations for
prophylactic percutaneous endoscopic gastric tube placement. For those patients who do
not require prophylactic PEG tube placement, the APRN can work collaboratively with
the Registered Dietician (RD) to monitor patient’s nutritional status using validated
malnutrition screening tools. Tracking patient’s weight, body mass index, total protein,
and albumin changes in addition to malnutrition screenings can be useful to identify
patients who may require reactive PEG tube placements. The APRN helps to coordinate
care and has appropriate referral processes in place to expedite surgical placement of
these tubes for patients with Head and Neck cancer.
Another innovative APRN strategy to enhance Head and Neck cancer patients
overall nutritional status is in the development of a pre-habilitation clinic. An
interdisciplinary approach to the care of the Head and Neck cancer patient would provide
advanced practice nurse assessment and medical management prior to cancer treatment
initiation. The multidisciplinary team of registered dieticians, physical therapists, speech
and language pathologists, social workers, case managers and chaplains could facilitate
patient centered care, improve patient satisfaction, and enhance overall outcomes.
Patients and families would be educated early to prepare patients for cancer treatment and
allow for early interventions to enhance patients overall nutritional status.
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A follow up clinic led by advanced practice nurses can allow for more frequent
outpatient visits and more intense symptom management once active treatment has
started. Frequent follow up appointments for patients in active treatment may decrease
emergency room visits, prevent admissions, enhance nutritional outcomes, and improve
quality of life. The APRN plays a pivotal role in improving health care value and
potentially decreasing the burden on the healthcare system by avoiding inappropriate use
of healthcare resources by preventing unnecessary emergency room visits and avoiding
admissions.
This study identified that despite the timing of percutaneous endoscopic gastric
tube placement, all patients lost weight and had worse nutritional outcomes upon
treatment completion. In addition, the timing of PEG tube placement did not always
coincide with artificial nutrition initiation. Sixty-seven percent of patients with
prophylactic PEG tubes began using artificial nutrition an average of nineteen days after
the cancer treatment began. Additional research is needed to determine the factors
associated with delays in time to tube feed so that barriers to early nutritional support can
be identified and mitigated. Excellent nutrition management is essential to improve the
Head and Neck cancer patient’s overall wellbeing and minimize weight loss.
In conclusion, there is no consensus in the literature to guide appropriate timing
for percutaneous endoscopic tube placement in the Head and Neck cancer patient treated
with combination chemotherapy and radiation. Patient and provider preference continues
to be the mainstay for decision making. Randomized studies are needed in multicenter,
large cancer intensive sites with a high volume of Head and Neck cancer patients to
determine best timing of tube placement with the desired goal of achieving optimal
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nutritional outcomes. APRN’s must participate in and utilize current research to change
the standard of care in this complex patient population. Evidence-based practice and a
multi-disciplinary innovative approach may improve patient care and enhance nutritional
outcomes in this vulnerable patient population.
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